A detailed history of Legal & General Group PLC transactions in Merus N.V. stock. As of the latest transaction made, Legal & General Group PLC holds 43,177 shares of MRUS stock, worth $1.83 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
43,177
Previous 43,177 -0.0%
Holding current value
$1.83 Million
Previous $2.16 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$47.19 - $58.84 $84,281 - $105,088
1,786 Added 4.31%
43,177 $2.16 Million
Q2 2024

Aug 14, 2024

BUY
$39.81 - $60.2 $269,513 - $407,554
6,770 Added 19.55%
41,391 $2.45 Million
Q4 2023

Feb 15, 2024

SELL
$20.06 - $28.66 $37,070 - $52,963
-1,848 Reduced 5.07%
34,621 $952,000
Q3 2023

Nov 14, 2023

BUY
$20.13 - $27.29 $303,057 - $410,850
15,055 Added 70.3%
36,469 $859,000
Q2 2023

Aug 14, 2023

BUY
$18.33 - $27.18 $236,420 - $350,567
12,898 Added 151.46%
21,414 $563,000
Q1 2023

May 15, 2023

BUY
$14.25 - $20.5 $6,426 - $9,245
451 Added 5.59%
8,516 $156,000
Q4 2022

Feb 14, 2023

BUY
$12.8 - $23.66 $12,096 - $22,358
945 Added 13.27%
8,065 $124,000
Q3 2022

Nov 14, 2022

BUY
$18.64 - $28.93 $3,765 - $5,843
202 Added 2.92%
7,120 $143,000
Q2 2022

Aug 22, 2022

BUY
$13.98 - $29.25 $4,068 - $8,511
291 Added 4.39%
6,918 $156,000
Q4 2021

Feb 14, 2022

BUY
$20.0 - $32.29 $24,000 - $38,748
1,200 Added 22.11%
6,627 $211,000
Q3 2021

Nov 15, 2021

BUY
$16.48 - $27.23 $69,660 - $115,101
4,227 Added 352.25%
5,427 $119,000
Q1 2021

May 17, 2021

BUY
$16.14 - $29.11 $19,368 - $34,932
1,200 New
1,200 $25,000

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $1.95B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.